What is ImmunoScape?
ImmunoScape is a pioneering company specializing in immunomics, leveraging a sophisticated technology platform for high-resolution immune profiling and characterization of the human immune response. The company's proprietary Deep Immunomics platform integrates advanced techniques such as mass cytometry, single-cell sequencing, and cutting-edge computational bioinformatics, data analysis, and visualization tools. This comprehensive approach enables the generation of novel, reproducible immune profiling information, positioning ImmunoScape at the forefront of understanding complex biological systems.
How much funding has ImmunoScape raised?
ImmunoScape has raised a total of $39M across 3 funding rounds:
Unspecified
$11M
Unspecified
$14M
Other Financing Round
$14M
Unspecified (2020): $11M with participation from Utec, NPR Holdings, and Anzu Partners
Unspecified (2021): $14M led by University of Tokyo Edge Capital Partners, Anzu Partners LLC, and Edbi
Other Financing Round (2022): $14M supported by Anzu Partners and Edbi
Key Investors in ImmunoScape
Edbi
EDBI is a global investor based in Singapore, focusing on high-growth technology sectors since 1991. The company aims to create value and empower businesses to build sustainable legacies through strategic investments. EDBI's portfolio includes innovative companies in various fields, such as biotechnology, fintech, and telecommunications. Their mission is to catalyze growth and transform industries while uplifting lives.
Anzu Partners
Anzu Partners is an investment firm focused on breakthrough technologies in clean tech, industrial, and life sciences sectors, managing $1 billion in assets. The company collaborates with a diverse team of investors, operators, consultants, scientists, and engineers to support founders in bringing innovative solutions to market. Anzu provides expertise in business development, market positioning, and global connectivity to accelerate growth and deliver long-term value. Their intended clients include startups and companies in the industrial and life sciences sectors seeking investment and strategic support.
Utec
UTEC is a venture capital firm approved by the University of Tokyo, focusing on investing in startups that leverage exceptional intellectual property and talent to contribute to society. Established in April 2004, UTEC has raised approximately 130 billion yen and manages six venture capital funds, primarily supporting seed-stage startups. The firm collaborates with universities and research institutions both domestically and internationally to source impactful technologies and foster innovation. UTEC aims to address global challenges through transformative science and technology, emphasizing strong management teams and cross-border market opportunities.
What's next for ImmunoScape?
With substantial enterprise-level funding and strategic backing, ImmunoScape is poised for accelerated growth and market expansion. The recent capital infusion is expected to fuel further development of its Deep Immunomics platform, enhance its data analysis capabilities, and potentially broaden its application across therapeutic areas and research initiatives. This strategic investment suggests a focus on scaling operations, forging key partnerships, and solidifying its position as a leader in the high-resolution immune profiling market.
See full ImmunoScape company page
